RxDoctor Payments Data

Emilija Rosenthal, NP

Family · Dallas, TXNPI 1710485479

Payments from drug & device makers

$2,537in general payments, 2019–2025

Across 102 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$520
  • Merck$199
  • Theratechnologies Inc.$162
  • Janssen Products, LP$149
  • EMD Serono, Inc.$120
  • plus $375 from 8 others

What the payments were for

  • Food & beverage$2,38894%
  • Education$1496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,537 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$5,348
Medicare patients
13
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf95$418,312
BiktarvyBictegrav/Emtricit/Tenofov Ala70$253,803
TriumeqAbacavir/Dolutegravir/Lamivudi47$170,265
TivicayDolutegravir Sodium55$137,974
DovatoDolutegravir Sodium/Lamivudine41$120,079
PrezcobixDarunavir/Cobicistat32$83,977
GenvoyaElviteg/Cob/Emtri/Tenof Alafen18$65,692
DescovyEmtricitabine/Tenofov Alafenam22$46,199
OzempicSemaglutide22$19,850
JardianceEmpagliflozin21$12,911
LinzessLinaclotide15$7,136
VascepaIcosapent Ethyl13$6,419
Arnuity ElliptaFluticasone Furoate15$2,750
Gabapentin50$793
Albuterol Sulfate HfaAlbuterol Sulfate14$703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato$1,012$428,318143 claims
Janssen Products, LPSymtuza$149$418,31295 claims
GileadBiktarvy, Genvoya, Descovy$520$365,694110 claims
Johnson & JohnsonPrezcobix$119$83,97732 claims
Novo NordiskOzempic$77$19,85022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →